Literature DB >> 29779213

Differential toxicity of TAR DNA-binding protein 43 isoforms depends on their submitochondrial localization in neuronal cells.

Illari Salvatori1, Alberto Ferri1,2, Silvia Scaricamazza1,3, Ilaria Giovannelli1, Alessia Serrano4, Simona Rossi5, Nadia D'Ambrosi3, Mauro Cozzolino1,5, Andrea Di Giulio6, Sandra Moreno6, Cristiana Valle1,2, Maria Teresa Carrì1,3.   

Abstract

TAR DNA-binding protein 43 (TDP-43) is an RNA-binding protein and a major component of protein aggregates found in amyotrophic lateral sclerosis and several other neurodegenerative diseases. TDP-43 exists as a full-length protein and as two shorter forms of 25 and 35 kDa. Full-length mutant TDP-43s found in amyotrophic lateral sclerosis patients re-localize from the nucleus to the cytoplasm and in part to mitochondria, where they exert a toxic role associated with neurodegeneration. However, induction of mitochondrial damage by TDP-43 fragments is yet to be clarified. In this work, we show that the mitochondrial 35 kDa truncated form of TDP-43 is restricted to the intermembrane space, while the full-length forms also localize in the mitochondrial matrix in cultured neuronal NSC-34 cells. Interestingly, the full-length forms clearly affect mitochondrial metabolism and morphology, possibly via their ability to inhibit the expression of Complex I subunits encoded by the mitochondrial-transcribed mRNAs, while the 35 kDa form does not. In the light of the known differential contribution of the full-length and short isoforms to generate toxic aggregates, we propose that the presence of full-length TDP-43s in the matrix is a primary cause of mitochondrial damage. This in turn may cause oxidative stress inducing toxic oligomers formation, in which short TDP-43 forms play a major role.
© 2018 International Society for Neurochemistry.

Entities:  

Keywords:  Complex I; TDP-43; amyotrophic lateral sclerosis; localization; mitochondria; neurodegeneration

Mesh:

Substances:

Year:  2018        PMID: 29779213     DOI: 10.1111/jnc.14465

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  23 in total

Review 1.  TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Tingxiang Yan; George Perry; Xinglong Wang
Journal:  Mol Cell Neurosci       Date:  2019-08-21       Impact factor: 4.314

2.  Cytoplasmic mislocalization and mitochondrial colocalization of TDP-43 are common features between normal aged and young mice.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Ju Gao; Luwen Wang; Jingjing Liang; Xinglong Wang
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-25

3.  S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.

Authors:  Elaine Pirie; Chang-Ki Oh; Xu Zhang; Xuemei Han; Piotr Cieplak; Henry R Scott; Amanda K Deal; Swagata Ghatak; Fernando J Martinez; Gene W Yeo; John R Yates; Tomohiro Nakamura; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

4.  TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer's disease.

Authors:  Ju Gao; Luwen Wang; Chao Gao; Hiroyuki Arakawa; George Perry; Xinglong Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-10-31       Impact factor: 5.187

5.  Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target.

Authors:  Silvia Scaricamazza; Illari Salvatori; Giacomo Giacovazzo; Jean Philippe Loeffler; Frederique Renè; Marco Rosina; Cyril Quessada; Daisy Proietti; Constantin Heil; Simona Rossi; Stefania Battistini; Fabio Giannini; Nila Volpi; Frederik J Steyn; Shyuan T Ngo; Elisabetta Ferraro; Luca Madaro; Roberto Coccurello; Cristiana Valle; Alberto Ferri
Journal:  iScience       Date:  2020-04-21

Review 6.  Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS.

Authors:  Kazuhide Asakawa; Hiroshi Handa; Koichi Kawakami
Journal:  Cell Mol Life Sci       Date:  2021-03-11       Impact factor: 9.261

Review 7.  Disease-modifying effects of metabolic perturbations in ALS/FTLD.

Authors:  Ali Jawaid; Romesa Khan; Magdalini Polymenidou; Paul E Schulz
Journal:  Mol Neurodegener       Date:  2018-12-04       Impact factor: 14.195

8.  TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response.

Authors:  Peng Wang; Jianwen Deng; Jie Dong; Jianghong Liu; Eileen H Bigio; Marsel Mesulam; Tao Wang; Lei Sun; Li Wang; Alan Yueh-Luen Lee; Warren A McGee; Xiaoping Chen; Kazuo Fushimi; Li Zhu; Jane Y Wu
Journal:  PLoS Genet       Date:  2019-05-17       Impact factor: 5.917

9.  Histaminergic transmission slows progression of amyotrophic lateral sclerosis.

Authors:  Savina Apolloni; Susanna Amadio; Paola Fabbrizio; Giovanna Morello; Antonio Gianmaria Spampinato; Emanuele Claudio Latagliata; Illari Salvatori; Daisy Proietti; Alberto Ferri; Luca Madaro; Stefano Puglisi-Allegra; Sebastiano Cavallaro; Cinzia Volonté
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-04-24       Impact factor: 12.910

Review 10.  Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship.

Authors:  Niccolò Candelise; Illari Salvatori; Silvia Scaricamazza; Valentina Nesci; Henri Zenuni; Alberto Ferri; Cristiana Valle
Journal:  Metabolites       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.